INTEGRA LIFESCIENCES HOLDING (IART)
US4579852082 - Common Stock
Overall IART gets a fundamental rating of 5 out of 10. We evaluated IART against 193 industry peers in the Health Care Equipment & Supplies industry. While IART has a great profitability rating, there are some minor concerns on its financial health. IART is valued quite cheap, while showing a decent growth score. This is a good combination! These ratings would make IART suitable for value investing!
1. Profitability
1.1 Basic Checks
In the past year IART was profitable.
IART had a positive operating cash flow in the past year.
IART had positive earnings in each of the past 5 years.
Each year in the past 5 years IART had a positive operating cash flow.
1.2 Ratios
The Return On Assets of IART (1.79%) is better than 73.96% of its industry peers.
IART has a Return On Equity of 4.27%. This is in the better half of the industry: IART outperforms 75.52% of its industry peers.
IART has a Return On Invested Capital of 6.57%. This is amongst the best in the industry. IART outperforms 83.33% of its industry peers.
The Average Return On Invested Capital over the past 3 years for IART is in line with the industry average of 8.53%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.79% | ||
| ROE | 4.27% | ||
| ROIC | 6.57% |
ROA(3y)3.63%
ROA(5y)3.23%
ROE(3y)8.1%
ROE(5y)7.34%
ROIC(3y)6.75%
ROIC(5y)6.66%
1.3 Margins
Looking at the Profit Margin, with a value of 4.39%, IART is in the better half of the industry, outperforming 75.00% of the companies in the same industry.
In the last couple of years the Profit Margin of IART has remained more or less at the same level.
With an excellent Operating Margin value of 17.63%, IART belongs to the best of the industry, outperforming 91.15% of the companies in the same industry.
In the last couple of years the Operating Margin of IART has grown nicely.
With a decent Gross Margin value of 63.09%, IART is doing good in the industry, outperforming 61.46% of the companies in the same industry.
IART's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 17.63% | ||
| PM (TTM) | 4.39% | ||
| GM | 63.09% |
OM growth 3Y3.4%
OM growth 5Y2.16%
PM growth 3Y-23.36%
PM growth 5Y1.25%
GM growth 3Y-0.76%
GM growth 5Y-0.14%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), IART is destroying value.
Compared to 1 year ago, IART has less shares outstanding
The number of shares outstanding for IART has been reduced compared to 5 years ago.
IART has a worse debt/assets ratio than last year.
2.2 Solvency
IART has an Altman-Z score of 1.85. This is not the best score and indicates that IART is in the grey zone with still only limited risk for bankruptcy at the moment.
IART has a Altman-Z score (1.85) which is comparable to the rest of the industry.
The Debt to FCF ratio of IART is 20.52, which is on the high side as it means it would take IART, 20.52 years of fcf income to pay off all of its debts.
IART has a better Debt to FCF ratio (20.52) than 71.88% of its industry peers.
IART has a Debt/Equity ratio of 0.94. This is a neutral value indicating IART is somewhat dependend on debt financing.
The Debt to Equity ratio of IART (0.94) is worse than 76.56% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.94 | ||
| Debt/FCF | 20.52 | ||
| Altman-Z | 1.85 |
ROIC/WACC0.74
WACC8.82%
2.3 Liquidity
IART has a Current Ratio of 3.45. This indicates that IART is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 3.45, IART is in line with its industry, outperforming 52.60% of the companies in the same industry.
IART has a Quick Ratio of 2.18. This indicates that IART is financially healthy and has no problem in meeting its short term obligations.
IART's Quick ratio of 2.18 is in line compared to the rest of the industry. IART outperforms 44.79% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.45 | ||
| Quick Ratio | 2.18 |
3. Growth
3.1 Past
The earnings per share for IART have decreased by -7.46% in the last year.
IART shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 5.08% yearly.
IART shows a decrease in Revenue. In the last year, the revenue decreased by -1.03%.
The Revenue has been growing slightly by 0.92% on average over the past years.
EPS 1Y (TTM)-7.46%
EPS 3Y8.16%
EPS 5Y5.08%
EPS growth Q2Q-5.32%
Revenue 1Y (TTM)-1.03%
Revenue growth 3Y3.96%
Revenue growth 5Y0.92%
Revenue growth Q2Q-0.24%
3.2 Future
The Earnings Per Share is expected to grow by 13.76% on average over the next years. This is quite good.
The Revenue is expected to grow by 5.95% on average over the next years.
EPS Next Y5.05%
EPS Next 2Y9.11%
EPS Next 3Y9.63%
EPS Next 5Y13.76%
Revenue Next Year4.7%
Revenue Next 2Y5.26%
Revenue Next 3Y5.59%
Revenue Next 5Y5.95%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 9.32, the valuation of IART can be described as reasonable.
97.92% of the companies in the same industry are more expensive than IART, based on the Price/Earnings ratio.
IART is valuated cheaply when we compare the Price/Earnings ratio to 28.28, which is the current average of the S&P500 Index.
Based on the Price/Forward Earnings ratio of 8.87, the valuation of IART can be described as reasonable.
97.40% of the companies in the same industry are more expensive than IART, based on the Price/Forward Earnings ratio.
IART is valuated cheaply when we compare the Price/Forward Earnings ratio to 20.88, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 9.32 | ||
| Fwd PE | 8.87 |
4.2 Price Multiples
94.79% of the companies in the same industry are more expensive than IART, based on the Enterprise Value to EBITDA ratio.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of IART indicates a rather cheap valuation: IART is cheaper than 85.42% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 31.07 | ||
| EV/EBITDA | 8.67 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates IART does not grow enough to justify the current Price/Earnings ratio.
The decent profitability rating of IART may justify a higher PE ratio.
PEG (NY)1.85
PEG (5Y)1.84
EPS Next 2Y9.11%
EPS Next 3Y9.63%
5. Dividend
5.1 Amount
No dividends for IART!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
INTEGRA LIFESCIENCES HOLDING
NASDAQ:IART (5/3/2024, 7:00:01 PM)
After market: 28.89 0 (0%)28.89
+0.14 (+0.49%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap2.27B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 9.32 | ||
| Fwd PE | 8.87 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)1.85
PEG (5Y)1.84
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.79% | ||
| ROE | 4.27% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | 17.63% | ||
| PM (TTM) | 4.39% | ||
| GM | 63.09% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.41
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.94 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 3.45 | ||
| Quick Ratio | 2.18 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-7.46%
EPS 3Y8.16%
EPS 5Y
EPS growth Q2Q
EPS Next Y5.05%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-1.03%
Revenue growth 3Y3.96%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y